About: The effect of Arbidol Hydrochloride on reducing mortality of Covid-19 patients: a retrospective study of real world date from three hospitals in Wuhan

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The effect of Arbidol Hydrochloride on reducing mortality of Covid-19 patients: a retrospective study of real world date from three hospitals in Wuhan Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The effect of Arbidol Hydrochloride on reducing mortality of Covid-19 patients: a retrospective study of real world date from three hospitals in Wuhan
Creator	Wang, Ke Li, Dan Peng, Peng Chen, Xianxiang Shen, Lei Yao, Li Xu, Feng Wang, Bing Zhu, Qi Chung, Ungil Dai, Xiyong Fang, Xuemin Liu, Qibin Tian, Lu
Source	MedRxiv
abstract	BACKGROUND The worldwide COVID-19 pandemic develops rapidly. There is a pressing need to find an effective therapy. METHODS We have assembled a cohort consisting 504 hospitalized COVID-19. Information of patients characteristics and antiviral medication use during hospital stay is collected. The study objective is to evaluate the treatment efficacy of selected antiviral medications on mortality and lesion absorption based on chest CT scan. RESULTS The overall mortality rate was 15.67% in the cohort. Older age, lower SpO2 level, bigger lesion, early admission data, and the presence of pre-existing conditions were associated with higher mortality. After adjusting for sex, pre-existing condition, age, SpO2, lesion size, admission data, hospital, and anti-viral medications use, Arbidol and Oseltamivir use is associated with a reduction in mortality. The OR is 0.183 (95% CI, 0.075 to 0.446; p<0.001) for Arbidol and 0.220 (95% CI, 0.069 to 0.707; p=0.011) for Oseltamivir. Compared with patients taking neither Arbidol nor Oseltamivir, the OR is 0.253 (95% CI, 0.064 to 1.001; p=0.050) for patients taking Oseltamivir only; 0.190 (95% CI, 0.076 to 0.473; p<0.001) for patients taking Arbidol only; and 0.030 (95% CI, 0.003 to 0.310; p=0.003) for patients taking both, after adjusting for patients characteristics and Lopinavir/Ritonavir use. Similarly, Arbidol is also associated with faster lesion absorption after adjusting for patients characteristics as well as Oseltamivir and Lopinavir/Ritonavir use. CONCLUSIONS Arbidol is able to substantially associated with a reduction in mortality among hospitalized COVID-19 patients. The combination of Arbidol and Oselmativir may further associated with a reduction in mortality. There is no proven treatment benefit of Lopinavir/Ritonavir.
has issue date	2020-04-17(xsd:dateTime)
bibo:doi	10.1101/2020.04.11.20056523
has license	medrxiv
sha1sum (hex)	8933d3de44a0b88fc3843c05a710e41e84b0b6a3
schema:url	https://doi.org/10.1101/2020.04.11.20056523
resource representing a document's title	The effect of Arbidol Hydrochloride on reducing mortality of Covid-19 patients: a retrospective study of real world date from three hospitals in Wuhan
resource representing a document's body	covid:8933d3de44a0b88fc3843c05a710e41e84b0b6a3#body_text
is schema:about of	named entity 'cohort' named entity 'objective' named entity 'mortality' named entity '504' named entity 'CHEST CT SCAN' named entity 'PATIENTS' named entity 'MORTALITY' named entity 'LESION' named entity 'mortality' named entity 'based' named entity 'antiviral medications' named entity 'Hydrochloride' named entity 'preprint' named entity 'medical records' named entity 'malaria' named entity 'preprint' named entity 'respiratory syncytial virus' named entity 'Oseltamivir' named entity '95% CI' named entity 'antiviral drugs' named entity 'antiviral medications' named entity 'sampling bias' named entity 'CC-BY-ND' named entity 'Arbidol' named entity 'COVID' named entity 'Wuhan' named entity 'bronchitis' named entity 'sleep quality' named entity 'Lopinavir/Ritonavir' named entity 'preprint' named entity 'Oseltamivir' named entity 'lesion' named entity 'Arbidol' named entity 'Statistics in Medicine' named entity 'Arbidol' named entity 'Ribavirin' named entity 'Arbidol' named entity 'CC-BY-ND' named entity 'Oseltamivir' named entity 'Lopinavir/Ritonavir' named entity 'pre-existing conditions' named entity 'Wuhan' named entity 'peer-reviewed' named entity 'Arbidol' named entity 'antiviral medication' named entity 'lesion' named entity 'peer-reviewed' named entity 'sensitivity analysis' named entity 'COVID-19' named entity 'antiviral treatment' named entity 'Arbidol' named entity 'mortality rate' named entity 'preprint' named entity 'clinical trials' named entity 'NIH' named entity 'lesion' named entity 'peer-reviewed' named entity 'influenza' named entity 'oxygen' named entity 'medRxiv' named entity 'COVID' named entity 'Ethics committee' named entity 'lesion' named entity 'confounding' named entity 'spontaneous abortion' named entity 'CT scan' named entity 'COVID' named entity 'COVID' named entity 'goodness of fit' named entity '95% CI' named entity 'Lopinavir/Ritonavir' named entity 'preprint'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software